Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lee, Jasmine G ^a   Wu, Reen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 3; CISPLATIN; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; PEPTIDES AND PROTEINS; PROTEIN LC3I; PROTEIN LC3II; RAPAMYCIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LOW DRUG DOSE; LUNG ADENOCARCINOMA; PROTEIN MODIFICATION; WESTERN BLOTTING;

APOPTOSIS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; QUINAZOLINES; RNA INTERFERENCE; TOR SERINE-THREONINE KINASES; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84868306580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048532     Document Type: Article

References (69)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
3. Gámez-Pozo A, Sánchez-Navarro I, Nistal M, Calvo E, Madero R, et al. (2009) MALDI profiling of human lung cancer subtypes. PLoS One 4: e7731.
4. Pore MM, Hiltermann TJ, Kruyt FA (2010) Targeting apoptosis pathways in lung cancer. Cancer Lett doi:10.1016/j.canlet.2010.09.012.
5. Kelsey CR, Clough RW, Marks LB, (2006) Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J 12: 283-288.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
7. Tsang RY, Al-Fayea T, Au HJ, (2009) Cisplatin overdose: toxicities and management, Drug Saf. 32: 1109-1122.
8. Barabas K, Milner R, Lurie D, Adin C, (2008) Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 6: 1-18.
9. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H (2011) Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2214.
10. Steins MB, Reinmuth N, Bischoff H, Kindermann M, Thomas M (2010) Targeting the epidermal growth factor receptor in non-small cell lung cancer. Onkologie doi:10.1159/000322214.
11. Salomon DS, Brandt R, Ciardiello F, Normanno N, (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
12. Ennis BW, Lippman ME, Dickson RB, (1991) The EGF receptor system as a target for antitumor therapy. Cancer Invest 9: 553-562.
13. Nicholson RI, Gee JM, Harper ME, (2001) EGFR and cancer prognosis. Eur J Cancer 37Suppl 4: S9-15.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
15. Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol doi:10.1155/2011/165214.
16. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, et al. (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2571.
17. Sierra JR, Cepero V, Giordano S, (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9: 75.
18. Hsieh YC, Athar M, Chaudry IH (2009) When apoptosis meets autophagy: deciding cell fate after trauma and sepsis. Trends Mol Med doi:10.1016/j.molmed.2009.01.002.
19. Behrends C, Sowa ME, Gygi SP, Harper JW (2010) Network organization of the human autophagy system. Nature doi:10.1038/nature09204.
20. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, et al. (2011) Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer doi:10.1002/ijc.26374.
21. Maiuri MC, Criollo A, Kroemer G, (2010) Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J 29: 515-516.
22. Li X, Fan Z, (2010) The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70: 5942-5952.
23. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA, (2009) Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 4: e6251.
24. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, et al. (2010) Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 4: 577-586.
25. Kao CY, Huang F, Chen Y, Thai P, Wachi S, et al. (2005) Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol 175: 6676-6685.
26. Wu R, Martin WR, Robinson CB, St George JA, Plopper CG, et al. (1990) Expression of mucin synthesis and secretion in human tracheobronchial epithelial cells grown in culture. Am J Respir Cell Mol Biol 3: 467-478.
27. Wu R, Zhao YH, Chang MM, (1997) Growth and differentiation of conducting airway epithelial cells in culture. Eur Respir J 10: 2398-2403.
28. Slinker BK, (1998) The statistics of synergism. J Mol Cell Cardiol 30: 723-731.
29. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
30. Eskelinen EL (2011) The dual role of autophagy in cancer. Curr Opin Pharmacol doi: 10.1016/j.poph.2011.03.009.
31. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
32. Radoshevich L, Murrow L, Chen N, Fernandez E, Roy S, et al. (2010) ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell 142: 590-600.
33. Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, et al. (2009) Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 15: 907-913.
34. Kim HP, Han SW, Kim SH, Im SA, Oh DY, et al. (2008) Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 7: 607-615.
35. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, et al. (2011) Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Mol Pharm doi:10.1021/mp200270v.
36. Lo HW, Hung MC, (2007) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 96Suppl: R16-20.
37. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, et al. (2007) Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25: 2178-2183.
38. Shanker M, Willcutts D, Roth JA, Ramesh R, (2010) Drug resistance in lung cancer. Lung Cancer: Targets and Therapy 1: 23-26.
39. Škarda J, Hajdúc M, Kolek V, (2008) Drug resistance in lung cancer. Cancer Therapy 6: 377-388.
40. Miyashita T, Reed JC, (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157.
41. Sartorius UA, Krammer PH, (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97: 584-592.
42. Gossage L, Madhusudan S, (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577.
43. Li GM, (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18: 85-98.
44. Hefferin ML, Tomkinson AE, (2005) Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst) 4: 639-648.
45. Shrivastav M, De Haro LP, Nickoloff JA, (2008) Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147.
46. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
47. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
48. Zhang Z, LaFramboise T, Abdel-Rahman M, Levine A, Ma P, et al. (2010) Overexpression of axl as a novel acquired resistance mechanism in egfr-mutated non-small cell lung cancer cells. Oncotarget 1: 497-514.
49. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, et al. (2005) Irreversible inhibitors of the egf receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102: 7665-7670.
50. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, et al. (2007) Implication of the insulin-like growth factor-ir pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13: 2795-2803.
51. Habib AA, Chun SJ, Neel BG, Vartanian T, (2003) Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1: 219-233.
52. Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, et al. (2005) Multidrug transporter abcg2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor iressa (zd1839, gefitinib). Cancer Res 65: 1770-1777.
53. Lin CI, Whang EE, Abramson MA, Jiang X, Price BD, et al. (2009) Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery 146: 1208-1214.
54. Liu L, Yang M, Kang R, Wang Z, Zhao Y, et al. (2011) HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 25: 23-31.
55. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, et al. (1999) Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59: 59-65.
56. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, et al. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672-676.
57. Li X, Fan Z, (2010) The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70: 5942-5952.
58. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752.
59. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. (2009) Autophagy mediates the mitotic senescence transition. Genes Dev 23: 798-803.
60. Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, et al. (2012) MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharma col 83: 16-26.
61. Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, et al. (2011) PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res 17: 5353-5366.
62. Hou H, Zhang Y, Huang Y, Yi Q, Lv L, et al. (2012) Inhibitors of Phosphatidylinositol 3'-Kinases Promote Mitotic Cell Death in HeLa Cells. PLoS One 7: e35665 doi:10.1371/journal.pone.0035665.
63. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, et al. (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 7: 2977-2987.
64. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, et al. (2004) Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res 64: 4030-4039.
65. Zhang J, Randall MS, Loyd MR, Dorsey FC, Kundu M, et al. (2009) Mitochondrial clearance is regulated by Atg7-dependent and independent mechanisms during reticulocyte maturation. Blood 114: 157-164.
66. Komatsu M, Wang QJ, Holstein GR, Friedrich VL Jr, Iwata J, et al. (2007) Essential role of autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A104: 14489-14494.
67. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, et al. (2011) The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 208: 455-467.
68. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, et al. (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885-889.
69. Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, et al. (2007) The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A 104: 14050-14055.